Myeloproliferative Disorders 
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Myeloproliferative Disorders
PHCHBS-WD4070, NCT00718263: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Checkmark In 2nd line CML chronic phase pts
Feb 2014 - Feb 2014: In 2nd line CML chronic phase pts
Active, not recruiting
3
90
Japan, US, Europe, RoW
Nilotinib, Imatinib
Novartis Pharmaceuticals
Myelogenous Leukemia, Chronic
10/18
10/18
NCT00302016 / 2005-001818-41: Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

No Longer Available
N/A
US, Canada, Europe, RoW
AMN107
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
11/08
 
NCT00413270: Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

No Longer Available
N/A
Canada
nilotinib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
 
 
NCT01549548: Compassionate Use Ponatinib

No Longer Available
N/A
US
Ponatinib, AP24534
OHSU Knight Cancer Institute, Ariad Pharmaceuticals
Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia
 
 

Download Options